Treating patients with a drug called aprotinin reduces the risk of stroke by 47 percent in patients undergoing coronary artery bypass graft (CABG) surgery, according to a study published in the Journal of Thoracic and Cardiovascular Surgery.
The study, a large-scale analysis evaluating data from 35 CABG studies, determined that use of aprotinin reduced the need for a blood transfusion by 39 percent. Blood transfusions during CABG surgery have been associated with an increased risk of stroke. Stroke and neurological injury occurs in five percent of the more than 300,000 CABG surgeries performed annually. "Our results highlight that aprotinin therapy might be recommended in all primary CABG surgeries after applicability to individual centers and patients is considered," said lead investigator Artyom Sedrakyan, M.D., researcher at Yale School of Medicine and lecturer at London School of Hygiene and Tropical Medicine. "About 10 strokes could be avoided in every 1,000 CABG patients with the use of aprotinin, which is a substantial stroke reduction benefit."
The study also showed that aprotinin therapy was associated with a trend toward reduced atrial fibrillation and did not increase the risk of adverse events including mortality, myocardial infarction and renal failure. "The cerebroprotective and anti-inflammatory effects of aprotinin therapy in CABG surgery, associated with improved neurological outcomes, have been reported in previous studies," said Sedrakyan, who did his work in the cardiothoracic department at Yale. "Our study further indicates that the balance of effects is positive with aprotinin use. Future studies should address the cost-effectiveness of this medication as it is substantially more costly in America as compared to the United Kingdom or the rest of Europe."
Karen N. Peart | EurekAlert!
UC San Diego researchers develop sensors to detect and measure cancer's ability to spread
06.12.2018 | University of California - San Diego
New cancer immunotherapy approach turns immune cells into tiny anti-tumor drug factories
05.12.2018 | University of California - San Diego
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.
Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...
New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals
Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.
Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.
Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...
Scientists from the Theory Department of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science (CFEL) in Hamburg have shown through theoretical calculations and computer simulations that the force between electrons and lattice distortions in an atomically thin two-dimensional superconductor can be controlled with virtual photons. This could aid the development of new superconductors for energy-saving devices and many other technical applications.
The vacuum is not empty. It may sound like magic to laypeople but it has occupied physicists since the birth of quantum mechanics.
06.12.2018 | Event News
03.12.2018 | Event News
28.11.2018 | Event News
07.12.2018 | Life Sciences
07.12.2018 | Materials Sciences
07.12.2018 | Physics and Astronomy